Howard Belfer
Neurology · San Mateo, CANPI 1740206457
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.6% of the total across 234 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 19 manufacturers, the largest accounting for just 13.6% — the pattern of someone who eats at a lot of different presentations.
Across 234 payments — averaging $16.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Adamas Pharmaceuticals, Inc.$515
- SK Life Science, Inc.$457
- Acadia Pharmaceuticals Inc$451
- Neurocrine Biosciences, Inc.$366
- Teva Pharmaceuticals USA, Inc.$358
- Amgen$329
- plus $1K from 13 others
What the payments were for
- Speaking & faculty fees$772%
- Food & beverage$3,66397%
- Education$501%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Adamas Pharmaceuticals, Inc. | 42 | $515 |
| SK Life Science, Inc. | 22 | $457 |
| Acadia Pharmaceuticals Inc | 30 | $451 |
| Neurocrine Biosciences, Inc. | 22 | $366 |
| Teva Pharmaceuticals USA, Inc. | 22 | $358 |
| Amgen | 13 | $329 |
| Eisai Inc. | 31 | $309 |
| AbbVie(2 entities) | 11 | $177 |
| Avanir Pharmaceuticals, Inc. | 8 | $162 |
| Biohaven Pharmaceuticals, Inc. | 7 | $153 |
| UCB, Inc. | 7 | $142 |
| Acorda Therapeutics, Inc | 4 | $77 |
| Kyowa Kirin, Inc. | 4 | $72 |
| EMD Serono, Inc. | 2 | $60 |
| Lilly USA, LLC | 3 | $53 |
| Bausch Health US, LLC | 2 | $36 |
| Pfizer | 2 | $27 |
| Tanabe Pharma America, Inc. | 1 | $27 |
| Biogen | 1 | $20 |
How this compares
$3,790 in reported general payments places this provider in the 65th percentile of 1,996 neurology providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Levetiracetam | 88 | $4,712 |
| Carbidopa-Levodopa-EntacaponeCarbidopa/Levodopa/Entacapone | 12 | $2,840 |
| Topiramate | 60 | $2,225 |
| AmantadineAmantadine Hcl | 44 | $1,846 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 40 | $1,767 |
| Carbamazepine | 29 | $1,280 |
| Gabapentin | 41 | $1,193 |
| Divalproex Sodium | 29 | $1,082 |
| Primidone | 52 | $1,073 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 35 | $1,002 |
| Ropinirole Hcl | 22 | $871 |
| Rasagiline Mesylate | 12 | $836 |
| Phenobarbital | 35 | $835 |
| Sumatriptan Succinate | 28 | $745 |
| Lamotrigine | 21 | $594 |
Paid to pharmacies, not to this prescriber.
Other neurology in San Mateo
- Andrew BlumenfeldCarlsbad$4.9M
- Khashayar DashtipourLoma Linda$3.3M
- Regina BerkovichWest Hollywood$3M
- Daniel BandariNewport Beach$2.6M
- Perry ShiehLos Angeles$2.4M
- Sandeep ThakkarIrvine$2M
- David LiebeskindLos Angeles$1.9M
- Jack SchimCarlsbad$1.7M
- Parshaw DorrizMission Viejo$1.5M
- Benjamin FrishbergCarlsbad$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.